
    
      -  Participants will be given a supply of SU011248 capsules to take at home in the morning
           for two weeks. After taking the capsules for two weeks, there will be a one-week rest
           period.

        -  Irinotecan will be administered on days 1 and 8 of every 21-day cycle as an intravenous
           infusion over 90 minutes. Cetuximab will be administered intravenously on days 1, 8 and
           15 of every 21-day cycle. The first treatment of cetuximab is a larger dose. Beginning
           with the second treatment, the participant will receive a smaller dose of cetuximab.

        -  Blood work will be repeated at every clinic visit on days 1 and 8. During cycle 1, blood
           will also be drawn on day 15.

        -  Tumor assessments will be repeated after 6 weeks, 12 weeks, and every 9 weeks
           thereafter, and will be assessed by both a CT scan of the abdomen, pelvis, and a chest
           x-ray. MUGA scans will be repeated every 4 cycles (12 weeks).

        -  Participants may continue to receive cycles of study treatment as long as their disease
           does not progress and they do not experience any serious side effects.
    
  